Integrated Filing — IndAS



General information about company

Scrip Code 542665
NSE Symbol NEOGEN
MSEI Symbol NOTLISTED
ISIN INE136S01016
Name of company Neogen Chemicals Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 31-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 28-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Specialty Chemicals
Start date and time of board meeting 31-10-2026   14:31:00
End date and time of board meeting 31-10-2026   19:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 29,596.00 54,625.00
Other income 396.00 782.00
Total income 29,992.00 55,407.00
2 Expenses
(a) Cost of materials consumed 23,488.00 41,490.00
(b) Purchases of stock-in-trade 0.00 74.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (7,143.00) (11,843.00)
(d) Employee benefit expense 3,096.00 5,626.00
(e) Finance costs 2,778.00 4,860.00
(f) Depreciation, depletion and amortisation expense 879.00 1,699.00
(f) Other Expenses
1 Other expenses 5,623.00 9,922.00
2 Share of profit (loss) of associates and joint ventures accounted for using equity method (1.00) (21.00)
Total other expenses 5,622.00 9,901.00
Total expenses 28,720.00 51,807.00
3 Total profit before exceptional items and tax 1,272.00 3,600.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 1,272.00 3,600.00
6 Tax expense
7 Current tax 629.00 1,232.00
8 Deferred tax (180.00) (166.00)
9 Total tax expenses 449.00 1,066.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 823.00 2,534.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 823.00 2,534.00
17 Other comprehensive income net of taxes (94.00) (77.00)
18 Total Comprehensive Income for the period 729.00 2,457.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 3,002.00 3,002.00
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.96 9.21
Diluted earnings (loss) per share from continuing operations 2.96 9.21
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.96 9.21
Diluted earnings (loss) per share from continuing and discontinued operations 2.96 9.21
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. Additional disclosures pursuant to regulation 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended: Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated May 22, 2024 as amended from time to time, the Neogen Chemicals Limited (“Holding Company”) has listed Non-Convertible Debentures (NCDs) on Bombay Stock Exchange (BSE). 1. The Company is rated by leading credit rating agency Crisil Ratings Limited (Crisil). Crisil has downgraded the rating on July 17,2026 to Crisil A2+ from Crisil A1and Crisil A-/Negative from Crisil A/Negative for its short-term facilities and long-term facilities (including NCDs) respectively. Pursuant to the rating downgrade the coupon rate of the said NCDs of Rs. 200 crore has increased from 10.50% p.a. to 11.00% p.a. effective from July 17, 2026. Crisil has revised Outlook from negative to stable as on September 25,2026 for its long-term facilities. 2. The above unaudited Consolidated financial results of the Company for the quarter and half year ended September 30, 2026 have been prepared in accordance with the IND AS, as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 as amended and the other accounting principles generally accepted in India and are in compliance with the disclosure requirement of Regulations 33 and Regulations 52 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended and were reviewed by the Statutory Auditor and recommended by the Audit Committee in its meeting held on October 31, 2026, to the Board for approval and was approved by the Board of Directors at their meeting held on October 31, 2026. 3. Consolidated financial results comprises the audited financial results of Neogen Chemicals Limited (“Holding Company”), Dhara Fine chem Industries (a joint venture where the Holding Company is holding 90% of the capital contribution), the wholly owned subsidiaries of the Company namely Neogen lonics Limited and Neogen Chemicals Japan Corporation Limited and the step down subsidiary of the Company Neogen Morita New Materials Limited(ceases from wholly owned subsidiary w.e.f October 02, 2026) which was incorporated on July 30, 2025, together known as the “Group”. 4. During the quarter and half year ended September 30, 2026, the Company completed a Qualified Institutions Placement (“QIP”) in accordance with Chapter VI of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and other applicable provisions. Pursuant to the QIP, the Company allotted 26,60,753 equity shares of face value Rs.10 each at an issue price of Rs. 2255 per equity share, including a securities premium of Rs. 2245 per share, to eligible qualified institutional buyers. The issue was completed on September 16,2026, aggregating to gross proceeds of Rs. 600 Crore. After deducting issue-related expenses of Rs. 20 Crore, the net proceeds amounted to Rs. 580 Crore. The proceeds are proposed to be utilised towards Repayment/ pre-payment, in full or part, of certain borrowings; Funding our long-term working capital requirements and General corporate purposes, in accordance with the placement document. During the quarter, an amount of Rs.230.35 was utilised towards the aforesaid objects, and the balance unutilised proceeds as at 30 September,2026 amounted to Rs.349.65. Consequent to the allotment, the paid-up equity share capital of the Company increased by Rs. 2.66 Crore, and the securities premium account increased by Rs.597.34, before considering any applicable adjustments for issue expenses. 5. On March 05, 2025, there was fire at Multi-Purpose Plant (MPP3) Facility, Tank Farms and warehouse at Dahej SEZ Plant of the Group. This incident led to damage of certain property, plant and equipment, inventory and interrupted business. The Group is adequately insured for reinstatement value of damaged fixed assets, inventory and loss of profits due to business interruption. The Group has intimated the fire incident with the insurance company and submitted loss estimate pertaining to replacement value of the damaged property, plant and equipment, loss of damaged inventory and incidental expenses incurred on account of fire. The Claim is admitted by the insurance company. During the quarter and financial year ended March 31, 2025, the Group has recognised loss of Rs. 362.90 Crore on account of damage to certain property, plant & equipment, inventory and estimated cost of incidental charges. The Group has recognised insurance claim receivable of Rs. 348.82 Crore to the extent of recovery of loss after adjusting applicable deductibility considering its assessment of loss and admissibility of claims as per the policy, adequacy of coverage and nature of loss and based upon the independent opinion obtained by the Group from Independent Surveyor and Independent Expert Practitioner. The Group has not accounted claim for loss of profit due to business interruption and excess value of reinstatement of assets over written down value as per accounting conservatism. The aforementioned losses and corresponding insurance claim has been presented on a net basis of Rs. 14.08 Crore under exceptional item and claim receivable in other current financial assets in these consolidated financial results for the quarter and financial year ended March 31, 2025. The Group has received Rs. 164.49 Crore (Rs. 155.00 Crore as on account payment from insurance company and balance Rs. 9.49 Crore pertains to sale of scrap) and incurred further incidental charges of Rs. 1.41 Crore which is also claimed as per insurance policy upto September 30,2026. Accordingly, net claim receivable as on September 30, 2026 is Rs. 185.74 Crore Subsequent to the quarter ended September 30,2026, The Insurance company has approved for an additional claim amount of Rs.. 152.00 crore to be released in due course of time, as part payment out of the entire claim receivable. 6. The Board of Directors of the Neogen Morita New Materials Limited (“NML”) had at its meeting held on September 26, 2026, inter alia considered and approved the issuance of 7,20,000 Equity Shares of the NML of a face value of Rs. 10/- each (“Equity Shares”) at a price of Rs. 1,066.66 per Equity Share including a premium of Rs. 1,056.66 per Equity Share, rounded off to an aggregate amount of Rs. 76,80,00,000 (Rupees Seventy Six Crore Eighty Lakh only), on a preferential basis to Morita Investment Limited (“MIL”) a wholly owned subsidiary of Morita Chemicals Industries Co. Limited in accordance with the Agreement entered into by the Neogen Ionics Limited and MIL on August 31, 2025 and applicable provisions of the Companies Act, 2013 and other applicable laws, as amended,. The said Preferential Issue was also duly approved with requisite majority by the shareholders of the NML at its Extra-Ordinary General Meeting held on September 26, 2026.Allotment of the shares was completed on October 2, 2026, and since then the NML ceases to be the wholly owned subsidiary of the Neogen Ionics Limited. 7. The Board of Directors of the Company, at its meeting held on March 7, 2026, inter alia approved the issue and offer of 10,00,000 equity shares of face value of Rs. 10 each at a price of Rs. 1,610 per Equity Share including a premium of Rs. 1,600 per Equity Share, aggregating to Rs. 1,61,00,00,000 (Rupees One Hundred and Sixty One Crore only) on preferential basis for cash consideration. Subsequently, the shareholders of the Company at its Extra Ordinary General meeting (EGM) held on March 29, 2026, has approved issue, offer and allotment of the said 10,00,000 equity shares to Cadamba Solutions Private Limited, a Promoter Group member of the Company. The allotment of the said equity shares of the Company on a preferential basis was done on April 18, 2026. The Equity Shares were listed on BSE Limited and National Stock Exchange of India Limited. Further we hereby confirm that there have been no deviations in the use of proceeds of issue of equity shares on preferential basis from the objects stated in the Notice dated March 7, 2026 for EGM held on March 29,2026 read with corrigendum to the said notice of EGM dated March 17, 2026 , for the quarter ended June 30,2026 and the intimation in this regard is being made available at https://neogenchem.com/announcements/ under the tab issue of securities and at the website of BSE Limited at https://www.bseindia.com/stock-share-price/neogen-chemicals-ltd/neogen/542665 and of National Stock exchange of India Limited at https://www.nseindia.com/get-quote/equity/NEOGEN/Neogen-Chemicals-Limited .



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 62,563.00
Capital work-in-progress 1,18,712.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 51.00
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 45.00
Trade receivables, non-current 0.00
Loans, non-current 23.00
Other non-current financial assets
1 Other non-current financial assets 1,775.00
Total of other non-current financial assets 1,775.00
Total non-current financial assets 1,843.00
Deferred tax assets (net)
Other non-current assets
1 Other non-current assets 17,254.00
Total of other non-current assets 17,254.00
Total non-current assets 2,00,423.00
2 Current assets
Inventories 75,260.00
Current financial asset
Current investments 0.00
Trade receivables, current 30,447.00
Cash and cash equivalents 44,446.00
Bank balance other than cash and cash equivalents 1.00
Loans, current 34.00
Other current financial assets
Total of other current financial assets 26,959.00
Total current financial assets 1,01,887.00
Current tax assets (net)
Other current assets
1 Other current assets 22,947.00
Total of other current assets 22,947.00
Total current assets 2,00,094.00
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 4,00,517.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 3,002.00
Other equity 1,54,749.00
Total equity attributable to owners of parent 1,57,751.00
Non controlling interest 0.00
Total equity 1,57,751.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 85,932.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease liabilities 5,799.00
2 Other non-current financial liabilities 250.00
Total of other non-current financial liabilities 6,049.00
Total non-current financial liabilities 91,981.00
Provisions, non-current 1,374.00
Deferred tax liabilities (net) 1,000.00
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 94,355.00
Current liabilities
Current financial liabilities
Borrowings, current 70,033.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,728.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 41,327.00
Total Trade payable 43,055.00
Other current financial liabilities
1 Lease liabilities 2,325.00
2 Other financial liabilites 30,435.00
Total of other current financial liabilities 32,760.00
Total current financial liabilities 1,45,848.00
Other current liabilities 2,563.00
1 Other current liabilities 1,432.00
2 Short term provisions 637.00
3 Current tax liabilites (net) 494.00
Total of other current liabilities 2,563.00
Provisions, current 0.00
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 1,48,411.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 2,42,766.00
Total equity and liabilites 4,00,517.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss (122.00) (96.00)
Total Amount of items that will not be reclassified to profit and loss (122.00) (96.00)
2 Income tax relating to items that will not be reclassified to profit or loss (29.00) (23.00)
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss (1.00) (4.00)
Total Amount of items that will be reclassified to profit and loss (1.00) (4.00)
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (94.00) (77.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3,600.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 4,860.00
Adjustments for decrease (increase) in inventories (18,438.00)
Adjustments for decrease (increase) in trade receivables, current 7,455.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (5,419.00)
Adjustments for decrease (increase) in other non-current assets (3,010.00)
Adjustments for other financial assets, non-current (224.00)
Adjustments for other financial assets, current 1,253.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (1,183.00)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (9,210.00)
Adjustments for increase (decrease) in other non-current liabilities 126.00
Adjustments for depreciation and amortisation expense 1,699.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 7,851.00
Adjustments for other financial liabilities, non-current (274.00)
Adjustments for unrealised foreign exchange losses gains (49.00)
Adjustments for dividend income 0.00
Adjustments for interest income 405.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (109.00)
Other adjustments for non-cash items 67.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (15,010.00)
Net cash flows from (used in) operations (11,410.00)
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 1,274.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (12,684.00)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 41,964.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 343.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 2,671.00
Net cash flows from (used in) investing activities (38,950.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 74,145.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 302.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 35,177.00
Repayments of borrowings 11,986.00
Payments of lease liabilities 1,046.00
Dividends paid 274.00
Interest paid 7,808.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 7,680.00
Net cash flows from (used in) financing activities 95,586.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 43,952.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 43,952.00
Cash and cash equivalents cash flow statement at beginning of period 494.00
Cash and cash equivalents cash flow statement at end of period 44,446.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results No
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s. Chandabhoy & Jassoobhoy, Chartered Accountants Yes 31-10-2029